1276 Rec'd PCT/PTO 07 JUL 2006

Docket No. 3443-4006 CUSTOMER NO. 27123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Masao SHIOZAKI a	nd Takaichi	SHIMOZATO
		~	A . TT **

Group Art Unit: TBA

Serial No.: TBA

Examiner:

TBA

Filed:

HEREWITH (July 7, 2006)

For:

LEFT-SIDE GLUCOSE LIPID A ANALOGUE

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

made of record to assist the Patent and Trademark Office in its examination of this application.
The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.
For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _______, filed

§§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are

1004103 v1

10/585640 Docket No. 3443-4006

Docket No. 3443-4006 Serial No. TBA

4.	\boxtimes		te is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement L ZUU it is being filed in compliance with:		
			37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or		
		\boxtimes	37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or		
			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or		
			37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.		
X	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Dep Account No. <u>13-4500</u> , Order No. <u>3443-4006</u> .				
			Respectfully submitted, MORGAN & FINNEGAN, L.L.P.		
Date	ed: Ju	ıly 7, 20	By: Mell Monand Reg. No. 33,285		

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile